Possible Interaction: Bumetanide and Gamma-Aminobutyric Acid

“ Bumetanide , a selective NKCC1 chloride importer antagonist, may attenuate depolarizing GABA action , and in that way reduce disease burden.”

“ Bumetanide has been reported to alter synaptic excitation–inhibition (E-I) balance by potentiating the action of γ-aminobutyric acid (GABA), thereby attenuating the severity of autism spectrum disorder (ASD) in animal models.”

“ Bumetanide , a selective NKCC1 inhibitor, works as a potent agent for restoring the inhibitory function of GABA.”

“ Bumetanide can decrease neuronal chloride concentrations and may thereby reinstate γ-aminobutyric acid (GABA)-ergic inhibition in patients with neurodevelopmental disorders.”

“Blocking early GABA depolarization with bumetanide results in permanent alterations in cortical circuits and sensorimotor gating deficits [published online ahead of print July 19, 2010].”

“ Bumetanide , a loop diuretic, inhibits the NKCC1 transporter and renders GABA inhibitory.”

“Recent data highlight the potential of bumetanide as a treatment for neonatal seizures and autism, as it facilitates the excitatory to inhibitory switch in gamma‐aminobutyric acid signalling.”

“Inhibition of NKCC1 with bumetanide reversed the paclitaxel effect on GABA-mediated hyperpolarization and GABA reversal potentials.”

“This EGABA shift was associated with increased expression of Na+–K+–2Cl− cotransporter 1 (NKCC1) in MNCs and was blocked by the NKCC inhibitor bumetanide as well as by decreasing NKCC activity through a reduction of extracellular sodium.”

“ Bumetanide partially reduced DF(GABA) and therefore the excitatory action of GABA in epileptic neurons.”